Transplantation Proceedings
Volume 35, Issue 5 , Pages 1644-1646, August 2003

Prostate-specific antigen in the assessment of organ donors

  • M.A Frutos

      Affiliations

    • Transplant Coordination Service, Hospital Universitario Carlos Haya, Malaga, Spain
    • Corresponding Author InformationAddress reprint requests to Dr Miguel A. de Frutos, Department of Nephrology, Hospital Universitario Carlos Haya, 29010 Malaga, Spain.
  • ,
  • D Daga

      Affiliations

    • Hospital Universitario Virgen de la Victoria, Malaga, Spain
  • ,
  • P Ruiz

      Affiliations

    • Transplant Coordination Service, Hospital Universitario Carlos Haya, Malaga, Spain
  • ,
  • J Jose Mansilla

      Affiliations

    • Transplant Coordination Service, Hospital Universitario Carlos Haya, Malaga, Spain
  • ,
  • M.V Requena

      Affiliations

    • Hospital Universitario Virgen de la Victoria, Malaga, Spain

Abstract 

Transplantation is limited worldwide by the shortage of organs, thus, donors of older ages are necessary to be used to meet the increasing demand for transplants. To minimize the transmission of cancer from this population, it is mandatory to rule out the presence of neoplasms. We present our experience with analysis of the prostate-specific antigen (PSA) for male donors older than 50 years of age. Eleven (5.9%) had PSA levels >6 ng/mL, 2 had prostate cancer. In 7 donors with high PSA levels postextraction study of the whole prostate gland showed carcinoma in 1 and prostate infarction in 1; the other 5 were reported as normal or having benign prostatic hypertrophy (BPH). Donors with high PSA levels are suitable for transplantation if urgent pathological studies do not find prostate cancer. Nevertheless, in most donors, increased PSA levels are secondary to causes other than malignant tumors, thus, the risk of transmission of prostate cancer with transplants is minimal. In conclusion, measurements of PSA levels alone prior to extraction are not sufficient to diagnose cancer in organ donors. We conclude that this analysis must be restricted to donors with a past history of prostate disease. Meanwhile, better tests to avoid false-positive results are required.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0041-1345(03)00691-2

doi:10.1016/S0041-1345(03)00691-2

Transplantation Proceedings
Volume 35, Issue 5 , Pages 1644-1646, August 2003